All In Biotech

Drug Trial Radar · NCT04619056

First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

First-in-man Clinical Trial to Assess Safety and Tolerability of CEB-01 PLGA Membrane in Patients With Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma After Surgery

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Jun 3, 2020

Primary completion

Nov 28, 2025

Study completion Nov 28, 2025

Sponsor

Lead sponsor
CEBIOTEXIndustry
Sponsor type
Industry
First posted
Nov 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, first-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma after surgery. The trial will be conducted in 3 dose-escalation cohorts (3 patients each, enrolling patients one by one, after 4 weeks of observation and agreement of Scientific Committee and DMC) and in an expansion cohort, using the highest safe and tolerable dose. The study will follow a 3+3 modified design; dose escalation will follow a modified Fibonacci method. CEB-01 carrying a SN-38 dose between 9 and 36 mg will be placed in the surgical bed at the time of tumor resection.

Conditions

  • Locally Advanced Soft Tissue Sarcoma
  • Recurrent Soft Tissue Sarcoma

Interventions

  • CEB-01 membrane loaded with SN-38Drug

    CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Doses for Phase II (Maximum tolerated dose)Time frame: Through 2 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalonia, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, Spain

  • Fundación Jiménez Díaz

    Madrid, Madrid, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.